These findings highlight the critical need for tumor genomic testing for all patients to identify those with high-risk tumors, which occur more frequently in Black women, and which require more aggressive treatment to prevent recurrence.

Using Fitbits, researchers set out to discover how many additional steps patients need to reduce risks of chronic disease.

Dataset grows to more than 312,000 whole genomes with longitudinal clinical data. GSK is one of the first to lead a further expansion of 50,000 whole genomes paired with proteomic data.

While diltiazem remains an effective option for heart rate control in selected patients, bleeding risk posed by anticoagulants should be considered.

The findings could suggest ways to intervene before clinical symptoms of memory and cognitive impairment become apparent.

The study advances understanding of risk for colon and rectal cancers and points to targets for developing new treatments.

The findings could bring relief to the more than 26 million people in the United States with asthma, a chronic and complex inflammatory disease of the airways.